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ABSTRACT: The rise of the biological causation model in the past thirty years is traced to
psychiatry’s efforts to regain lost status and to protect itself from intrusions by non-medical
practitioners, as well as to the pharmaceutical industry’s drive for profits. Evidence in support of
the model, including studies of identical twins and of brain structure and function, are less
revealing than was earlier thought, due to problems in methodology and interpretation. Organized
psychiatry, when challenged in 2003, was unable to provide compelling evidence for biological
causation of most mental and behavioral disorders. A paradigm shift away from biological
causation and toward environmental causation is called for.
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The term “biological psychiatry” describes a phenomenon of increasing visibility in
both the professional and popular cultures in the past thirty years. It reflects growing
acceptance of the notion that chemical imbalances, genetic defects and related biological
phenomena cause disorders such as schizophrenia, depression, anxiety, substance abuse,
and attention deficit hyperactivity disorder (ADHD). As biological causation has gained
attention, acceptance of environmental causation has necessarily declined, and
psychotropic medications have become the treatment of choice for mental and behavioral
disorders (Antonnucio, Danton & DeNelsky, 1995).
However, an examination of the contributing variables, not all of which are
empirical, suggests that the research in support of biological causation is weaker than one
would expect, given its increased acceptance over the past three decades. Similarly, there
are reasons to think that the claims of drug effectiveness are at times overstated
(Glenmullen, 2002; Hubbard & Wald, 1997; Valenstein, 1998).
PSYCHIATRY’S ANXIOUS YEARS
To understand the rise of biological psychiatry’s influence, it is necessary to
examine the changing public face of psychiatry over the past few decades. “Psychiatry’s
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Anxious Years” was the title of an early 1980s New York Times article (Nelson, 1982)
that described an evident crisis in psychiatry, and psychiatry’s reaction to that crisis. The
percentage of medical school graduates opting for careers in psychiatry had dropped by
more than half from 1970 to 1980, from 11% to 5%. The Times article listed several
reasons why decreasing numbers of young physicians had opted for careers in psychiatry.
The reasons included the relatively low pay of psychiatrists and increasing interest in
family practice. There were additional reasons that foreshadowed a return to an increased
emphasis upon the connection between biology and behavior. First, many medical school
graduates had developed the perception that psychiatrists had become “dinosaurs,” mired
in pits of psychoanalytic confusion. Also, young physicians were not buying into fringe
treatments such as primal scream therapy and nude encounter groups that had arisen
within the mental health arena during the 1960s. The Times article described the efforts
of organized psychiatry to reverse the trend by doing two things. It held recruitment
strategy conferences such as one in San Antonio in the late 1970s, and it began to
emphasize science, or what passed for science—to advocate a return to biological
explanations of mental illness (Nelson, 1982).
As psychiatry was returning to biological causation, another concern emerged.
Movement into the treatment field by non-physicians such as clinical psychologists,
clinical social workers, psychiatric nurses, counselors and others was escalating. As the
1980s, 1990s and early years of the new century played out, the battles over Medicare
reimbursement, hospital privileges and prescription privileges were joined. Those
disputes continue today (APA Deplores, 2004). The related professions have gradually
gained ground. By the early 1990s psychologists had won the right to treat Medicare
patients without physician supervision (Buie, 1990). The military’s successful effort to
train psychologists to safely prescribe psychotropic medications has boosted state
legislation of the same kind. In response to one such effort, a news release from the
American Psychiatric Association was headlined “APA deplores Louisiana Governor’s
decision to sign psychologist’s prescribing bill” (APA Deplores, 2004). On November 5,
2004, the American Psychiatric Association’s Board of Trustees announced creation of a
task force to review the psychology prescription issue and to put “an end to
psychologists’ bid to win prescription privileges throughout the United States”
(Psychiatry names, 2004). Despite the efforts of organized psychiatry, psychology and
related disciplines continue to gain ground in the prescription privileges debate
(Bradshaw, 2004).
Attacks upon related professions by organized psychiatry are not new. Such
criticisms frequently have appeared in highly visible sources, and have tended to advise
psychiatrists to turn to biological causation theory. Seldom mentioned is the fact that
there exists minimal research evidence to demonstrate that, for example, most cases of
depression are caused by a chemical imbalance. More than two decades ago an article in
Hospital and Community Psychiatry (Bursten, 1981) stated, in part, that “medicalization”
of disorders is useful “to rally the troops…to thwart the attackers…Economics demands
that we be medical…we use the term to rout the enemy within.” The same year, readers
of the American Journal of Psychiatry were urged to “…speak with a united voice not
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only to secure support but to buttress (psychiatry’s) position against the numerous other
mental health professionals seeking patients and prestige” (Havens, 1981). The call for
defense of psychiatry’s turf was clear, and the rhetoric continued through the 1980s.
In 1988 Paul Fink, then President-elect of the American Psychiatric Association,
stated that psychologists and other non-psychiatrists, “…don’t have the training to make
the initial evaluation and diagnosis…(and) are not trained to understand the nuances of
the mind…” (Wyatt, 2003). Elsewhere that year Melvin Sabshin, then Medical Director
of the American Psychiatric Association, in testimony before the New York State
Legislature, warned legislators of “The grave risks to health care…of psychologists’ self-
serving claimed advantages for their clients….” Sabshin asked, “Do the substantial and
inevitable risks to the quality of patient and medical care in hospitals outweigh the
dubious, purported benefits associated with hospital privileges for these non-physician
practitioners?” (Wyatt, 2003).
Psychiatry’s efforts to stem the twin tides of reduced interest among medical school
graduates and intrusion by non-physicians paralleled the rise of biochemical and genetic
explanations of abnormal behavior. Though often only weakly supported by research
evidence, medicalization of depression, anxiety and other disorders rapidly advanced in
the professional and popular cultures. By the late 1990s and early years of the new
century, biological causation had gained a great deal of ground with professionals, and
with the public. 
Claims that are published in respected sources and are then consumed by the
professional community may find their way to the popular media where they influence
public perceptions. For example, a 2002 article in People magazine described the extreme
discomfort around others that has plagued Miami Dolphins’ star running back Ricky
Williams. The article characterized Williams’ social anxiety disorder as a “…depression-
like chemical imbalance that affects roughly three million Americans…” (Tresnioweski,
Rozsa & Brass, 2002). However, to date there is no credible research to prove that social
anxiety disorder is caused by a chemical imbalance. The People article typifies the
present strength of the biological causation model in the popular culture. It is unfortunate
that misinformation is routinely purveyed to the public. Equally unfortunate is that such
statements are typically put forth as absolute fact, minus significant critical analysis.
However, recently several scholars have begun to question the trend toward
medicalization of disorders (Midkiff &Wyatt, 2005; Wong, 2005).
PHARMACEUTICAL COMPANY FINANCIAL INTERESTS
The suggestion that our biology is the source of disorders such as schizophrenia,
depression, anxiety, addiction, and numerous childhood disorders is heavily promoted by
the pharmaceutical industry. Biological causation suggests biological treatment, rather
than behavioral intervention. Study after study shows that in the past thirty years the sales
of psychotropic drugs have increased dramatically. Between 1985-1994 doctor visits at
which psychotropic drugs were prescribed increased 20%. The prescription of stimulants
tripled, and prescription of mood elevators doubled, to more than 20 million, during
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roughly the same time frame (Pincus, Tanielian, Marcus, Olfson, Zarin, & Thompson,
1998).
To achieve increased sales, the marketing practices of the pharmaceutical industry,
including the marketing of psychotropic drugs, have mushroomed. The industry spent
$19 billion on advertising in the United States alone in 2001. It has more lobbyists than
members of Congress, and it spent over $200 million on lobbying and campaign
contributions in 1999-2000, the largest amount of any industry (Antonuccio, Danton &
McClanahan, 2003).
The Center for Public Integrity reported that since 1998 the drug industry has
lobbied congress on more than 1,400 bills and spent $759 million on lobbying, while
employing 805 former federal officials as lobbyists. Within that group of lobbyists, more
than fifty were former members of the U.S. House of Representatives, and a dozen were
former senators (Ismail, 2005). Drug manufacturers flood physicians with free samples,
free books, free videos, free continuing education programs (typically touting the
company’s drugs), and more. For example, at the 2003 meeting of the American
Psychiatric Association in San Francisco, Pfizer (maker of anti-depressants Zoloft and
Sinequan) supported four continuing education symposia involving twenty presenters.
Each symposium included dinner for those in the audience. At the Pfizer display booth
copies of widely sold books The Memory Bible (Small, 2003) and The Quiet Room
(Schiller & Bennett, 1996) were distributed—with the books’ authors present to provide
autographs.
Since 1995 the drug industry has engaged in aggressive television, newspaper and
other direct-to-consumer advertising (Antonuccio, Danton & McClanahan, 2003).
Advertisements often tout biological causation, and frequently do so in absolute terms.
For example, a 1996 newspaper advertisement for the Wyeth company’s anti-depressant
Effexor stated, “Depression is a medical condition with proven treatment alternatives
available.” Contrary to the advertisement’s claim, there is minimal empirical evidence to
establish that more than a small minority of cases of unipolar depression (by far the most
frequently diagnosed type) may be attributable to biological causes (Antonuccio, Danton
& DeNelsky, 1995). Rather, it is likely that most such cases are due to factors such as
inadequately learned coping skills or, for those with good coping skills, overwhelming
stress.
Drug company advertising of mood and nerve medicines to physicians, including
family doctors, pediatricians and others not trained to practice psychiatry, has increased
as well. In 1990 the journal Pediatrics (Lucey, 2003) contained seven full-page
advertisements for stimulant medications used to treat ADHD. By 1995 that number had
risen to twelve, and by 2000 to fifteen (Wyatt, 2003). Medco Health Solutions Inc., the
nation’s largest prescription benefit manager, reported a 49% rise in the use of ADHD
drugs by children under five between 2001-2004, and a 23% increase in overall usage by
children. The nearly 50% increase with children under five translated to a 369% increase




The impact of direct-to-consumer advertising was demonstrated in a study published
in the Journal of the American Medical Association (Kravitz, Epstein, Feldman, Franz,
Azari, Wilkes, Hinton & Franks, 2005). In the study, 152 family doctors and internists
were visited unannounced 298 times by “patients”—actors trained to present with
symptoms of either major depressive disorder or adjustment disorder with depressed
mood. At some visits the patients mentioned the anti-depressant Paxil, adding that they
had seen an advertisement for the drug on television, and they asked the doctor whether it
might be of help. At other visits the patients told the doctors they had seen an ad for anti-
depressant medication, but they mentioned no specific drug. At still other visits the
patients made no reference to medication. Of the 51 visits in which Paxil was mentioned
by those with major depressive symptoms, 14 visits (27.4%) resulted in prescription of
that drug. By contrast, of the 50 visits in which there was general reference to
“medication,” only once (2.0%) was Paxil prescribed. When patients made no mention of
medication, Paxil was prescribed twice (4.2%). Findings were similar when patients
presented with symptoms of adjustment disorder.
The financial interests of the pharmaceutical industry have dovetailed with the guild
interests of organized psychiatry. Both have much to gain by promoting the biological
causation model of mental and behavioral disorders. By 2003 the drug industry was
underwriting 70% of all clinical drug trials in the United States and there were
accusations that negative studies were being terminated prior to publication (Antonuccio,
Danton & McClanahan, 2003). All of this was paying off for the pharmaceutical industry.
By 2001-2002 three psychotropic medications (Zyprexa, Zoloft and Paxil) were among
the top ten revenue producing prescription drugs in the United States. They accounted for
over $7.5 billion in sales. Each showed greater than 10% sales growth from 2001-2002.
(Vaczek, 2003). 
In 2003, reporters for the Knight-Ridder News Service launched an investigation of
a practice known as off-label prescribing (Young & Adams, 2003). Off-label is a term
used when a doctor prescribes medication for a specific disorder or disease for which that
drug has not been FDA approved. Although doctors may legally prescribe off-label, it is
illegal for drug companies to promote the practice. Frequently they do so anyway. “By
offering specialty drugs to non-specialists, sending salesmen to doctors’ offices and
medical conventions, and touting their drugs’ benefits on the slimmest of evidence,
pharmaceutical companies have sent off-label retail sales soaring” (Young & Adams,
2003). The investigation found that about 60% of anti-psychotic medication prescriptions
were off-label, prescribed for disorders such as Alzheimer’s, ADHD, insomnia and
autism. For antidepressants, not including the SSRI’s (selective serotonin re-uptake
inhibitors), about 40% of prescriptions were off-label.
The Knight-Ridder investigation disclosed that between 1994-2003 the number of
pharmaceutical sales representatives more than doubled to 94,000 (it has since topped
100,000), about one salesperson for every seven practicing physicians in the United
States. From 1996-2002 the value of free drug samples given to physicians increased
more than 140%, to $11.9 billion. The investigative reporters concluded in part,
“Promoting the growth (in off-label prescribing) is a symbiotic relationship between
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physicians and drug makers in which sales representatives routinely target doctors
untrained in the basics of drug therapy….”
Shifting trends in pharmaceutical industry jobs reflect the findings of the Knight-
Ridder investigation. According to Boston University’s Health Reform Program, which
obtained its data from the website of the drug manufacturer’s lobby group Pharmaceutical
Research and Manufacturers of America (PhRMA), from 1995-2000 the number of drug
industry jobs in research and development fell 2%, while the number of jobs in marketing
those drugs rose 59%, to nearly double those in R & D (Sagar & Socolar, 2001).
While the drug industry has aggressively engaged both physicians and the public in
order to maximize sales, safety of medications of all kinds is an ongoing concern. There
are suggestions that the pharmaceutical industry exerts undue influence over the Food
and Drug Administration, and that the agency is weak in carrying out one of its major
functions—protecting the public from harmful drug side-effects. Merck pulled its arthritis
pain-killer Vioxx from the market on September 30, 2004. FDA researcher David
Graham testified to congress that his superiors at the FDA had tried to block publication
of his research on the drug. Graham had discovered that Vioxx is associated with
increased risk of strokes and heart attacks. Graham said he was subjected to an
environment where he was “ostracized” and “subjected to veiled threats” and
“intimidation” by superiors who suggested that he water down his findings (Rubin,
2004). Later the FDA’s advisory committee voted 17-15 that, for some patients, Vioxx’s
benefits outweighed its risks. It was then disclosed that the majority of panel members
voting for Vioxx had received speaker’s honoraria, consulting fees or research money
from Merck, the company which manufacturers the drug. Similar disclosures were
brought to light regarding painkillers Bextra and Celebrex, and their maker Pfizer (Rubin,
2005).
In November, 2004, Bristol-Myers Squibb agreed to pay $70 million to settle a
class-action lawsuit with over two thousand users of its anti-depressant Serzone. While
the company continues to assert that the drug is safe, the lawsuit claimed that the drug
increases the likelihood of liver failure. Although the FDA had earlier required the
company to put a “black-box warning” on the drug’s packaging, that warning came about
only after more than a hundred of the drug’s users had reportedly developed serious liver
disorders. The company stopped selling Serzone prior to settlement of the lawsuit
(Coleman, 2004). Thus, with drug industry practices coming under increasing scrutiny, it
is not surprising that the industry’s impact upon the mental health field has garnered
attention as well.
Biological causation is the theoretical mortar that has cemented the marriage
between psychiatry and the pharmaceutical industry. However, research in support of
biological causation of mental disorders, and its counterpart, biological treatment,
appears to be less compelling than we are often led to believe. The two primary lines of
this research are family studies, especially studies of identical twins, and research into the




For many years the biological causation model has been bolstered by results of
studies of families, especially by similarities in identical twins. Identical (one-egg) twins
have identical genetic structure. When identical twins were studied and found concordant
for (when both developed) schizophrenia, anxiety disorders, substance abuse, chronic
depression or other disorders at rates above that of the general population, it was thought
that we had uncovered powerful evidence that genetic factors are causal. Other
researchers, thinking more critically, correctly surmised that such a conclusion was
unwarranted. That was because environmental factors (growing up in the same
dysfunctional home, for example) could not be ruled out as having caused the disorder.
For example, if one or both parents had been abusive or had been maladjusted in any
significant way, the home environment, rather than genes, might have been to blame.
There was no way to separate environmental variables from genetic variables. Thus,
researchers began to search for pairs of identical twins who had been separated soon after
their births and reared in different environments. Then any concordance for a mental
disorder could be attributed to genes. At least that was what behavioral scientists
believed.
Researchers found that identical twins’ concordance for various disorders was
indeed greater than population base rates, even if reared apart. For example, although the
population base rate for schizophrenia is generally said to be about 1%, the concordance
rates for schizophrenia in identical twins who have been separated soon after birth and
reared apart are typically presented, by authors of widely adopted textbooks, to be
anywhere from 15% to about 40%, depending upon the study (e.g., Comer, 2005; Sarason
& Sarason, 2002). Similar results are reported for other disorders. Such studies have long
been cited as providing powerful proof of genetic contributions to schizophrenia and
other mental disorders (Owen & O’Donovan, 2002).
Along the way, at least a few researchers had suspected that there were
methodological difficulties with the identical twin research (Farber, 1981; Watson, 1981;
Wyatt, 1993). The integrity of the studies rested upon an important assumption--that
when identical twins were reared apart, they necessarily had been reared in differing
environments. We now know the assumption was wrong.
Identical twins, even if reared apart, are alike in both physical appearance and rate of
maturation, factors that exert powerful influence upon one’s adjustment.
Given adequate nutrition, identical twins will both be handsome, homely or average
looking. Their worlds, even when far apart geographically, will tend to treat them
similarly based on their looks, and in ways that are known to contribute to mood and
overall adjustment. For example, a substantial body of research has documented that
attractive people tend to be treated better than unattractive people. Attractive people
receive more liking and desire for contact by others than do unattractive individuals
(Walster, Aronson, Abrahams, & Rottman, 1966). Others express a greater desire to date
them, and others evaluate attractive people more positively as prospective spouses
(Bynne, Ervin & Lamberth, 1970). Compared to unattractive people, good-looking
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individuals even get better grades on essays when the same essay is graded by two
professors who have been shown photos of attractive and unattractive “authors” (Landy
& Sigall, 1974). Researchers who have hitched their conceptual wagons to the twin study
star have seldom considered that unattractive twins likely are at increased risk for
depression, and perhaps other disorders, based on the ways that their environments treat
them, rather than on their genes.
Physical attractiveness is not the only source of environmental influence at work in
shaping the adjustment of children, including that of identical twins. Rate of maturation
also undercuts the assumption that identical twins, even those who were separated soon
after birth, necessarily have been raised in quite different environments. Identical twins
are likely to reach puberty at the same rate. Whether that development is early, at the
average age, or late has much to do with how young people feel about themselves and
how others respond to them. For example, early maturing girls tend to be below average
in popularity, withdrawn, lacking in self-confidence, psychologically more stressed and
they generally hold fewer leadership positions than their later-maturing peers (Ge,
Conger & Elder, 1996; Graber, Lewinson, Seeley & Brooks-Gunn, 1997; Jones &
Mussen, 1958). Also, they are more involved in behaviors such as getting drunk and
participating in early sexual activity and, on average, they achieve less well in school
(Caspi, Lynam, Moffitt & Silva, 1993; Dick, Rose, Viken & Kaprio, 2000). It would be
disingenuous to assert that the day-to-day feedback that adolescent girls receive regarding
their attractiveness and maturation is unrelated to contemporary or later problems in
adjustment, such as depression.
For boys the maturation trends are globally similar, though different in specifics.
With boys, early maturation is better than late maturation, at least superficially. Early
maturing boys are seen as relaxed and independent, and get more leadership positions in
school. Late maturing boys are viewed by others as anxious, too talkative and are seen as
seeking too much attention (Brooks-Gunn, 1988; Clausen, 1975; Jones, 1965; Mussen &
Jones, 1957). Interestingly, early maturing boys report greater psychological stress than
do their later maturing peers (Ge, Conger & Elder, 2001), contrary to how they are seen
by others. Identical twins mature at the same rate, even if reared apart, and as a result live
in worlds that treat them similarly in ways that have implications for adjustment,
including the development of mental and behavioral disorders.
Thus, environments bombard children with identifiable and differential classes of
feedback based upon the youngsters’ levels of physical attractiveness and rates of
maturation. Twin researchers have generally failed to account for this body of
developmental psychology research.
There are other reasons to doubt researchers’ long-held assumption that identical
twins who were separated soon after birth were necessarily reared in substantially
different environments. One issue is the reported ages at which the twins in the studies
were separated. One of the leading researchers in twin similarities reported that he had
studied 315 pairs of identical twins who had been reared apart “since age ten” (Lykken,
McGue, Tellegen & Bouchard, 1992). Unaccounted for is a flood of environmental water
that has gone over the life experience dam, prior to age ten.
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Additionally, family adoption practices and adoption agency practices further
muddy the genetic/environmental causation waters, when twin studies are looked at
closely. Reviews of a number of studies (Farber, 1991; Wyatt, 1993) revealed that
frequently the “separated” twins had been reared in the same extended family. Similarly,
when adoption is handled by an adoption agency, a biological parent often insists that the
infant be placed in a home similar to that of the biological parents with regard to religion,
ethnicity, socioeconomic status and population density (urban/rural setting). All are
variables that are known to correlate with various mental and behavioral disorders. When
separation of twins is not done soon after birth, and when adoption involves intentional
placement of the twins into similar environments, it becomes difficult or impossible to
separate genetic contributions from environmental contributions, when one attempts to
tease out the causes of later mental or behavioral disorders.
Physical attractiveness, rate of maturation, age of separation, and family and agency
adoption practices have typically been unaccounted for by researchers whose studies
show up to 40% concordance for mental disorders in identical twins who were reared
apart. Yet, cultural factors are powerful and often unyielding. Identical twins reared
“apart” are actually exposed to daily streams of similar environmental
pressures—influences that may well account for the reported levels of concordance for
emotional and behavioral disorders. Given all of this, it is reasonable to conclude that
genetic and environmental influences have been hopelessly confounded in the identical
twins studies.
It is likely that identical twin studies have done little more than confuse our
understanding of mental and behavioral disorders. In that respect there are similarities to
other misuses of genetic studies. At times other genetic studies have played unwarranted
roles in a number of social and political struggles. For example, alleged biologically
based IQ differences between races have been used to deny economic justice to African
Americans. Male domination over women has been justified on the basis of flawed
genetic studies as well. These issues will not be explored here. Extensive reviews are
available elsewhere (Lewontin, 1992; Lewinton, Rose & Kamin, 1984).
STUDIES OF BRAIN STRUCTURE AND FUNCTION
Apart from the identical twin studies, another line of research has at times been
touted as yielding convincing evidence of biological causation of behavioral disorders.
There are two primary threads to this line of research. The first is done on autopsy and
involves microscopic analyses of the cellular structure of the brain tissue of individuals
who had suffered mental disorders while living. These studies tend to consistently show
differential cell structure for those who were schizophrenic, depressed, etc., vis-à-vis
those who had suffered no disorder. Hypothetically, a typical study might show that 60%
of schizophrenics’ brains had contained excess amounts of the neurotransmitter
dopamine-4, while only 10% of the brains of normals had contained excess amounts of
the chemical. At first blush this would seem to provide compelling evidence that, for
many schizophrenics, excess dopamine-4 had played a major causal role in their disorder.
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However, there is another interpretation of those data, one that weakens any inferred
causal connection between the neurotransmitter and schizophrenia. Examination of the
absolute numbers reflected by the above percentages, 60% and 10%, provides a less
compelling picture. If one considers the adult (because schizophrenia is seldom
diagnosed in children) population of the United States to be roughly 200 million, then
there are about 2 million schizophrenics in the country (based on the commonly accepted
notion that about 1% of the population is schizophrenic). If 60% of them have excess
levels of dopamine-4, then it follows that about 1.2 million American schizophrenics
have excess amounts of the chemical in their brains. Then, not counting the 2 million
who are schizophrenic, there remain roughly 198 million American adults who are not
schizophrenic, 19.8 million (10%) of whom have excess dopamine-4. In this scenario the
non-schizophrenics outnumber the schizophrenics more than sixteen to one. It is difficult
to argue that an elevated neurotransmitter level is causal for a specific disorder when that
elevation is much more frequently found in individuals who never suffered from the
disorder. However, researchers tend to report percentages, minus extrapolated references
to the population numbers that follow logically from those percentages.
Apart from the autopsy studies, brain-imaging research has focused on the living.
Those studies employ technologies such as PET scans and fMRI. Frequently they reveal
interesting differences between the brains of the disordered and the brains of those with
no mental or behavioral disorder. Even so, it is not possible to infer either environmental
or biological causation from such studies. In part, that is because the direction of the
causality remains unknown.
Although it is tempting to conclude that a given mental disorder resulted from an
identified abnormality in brain structure or function, evidence from studies of both sub-
humans and humans makes clear that the disorder may have come before the brain
abnormality. Valenstein (1998) reviewed a number of studies in which the brains of
lower species were subjected to various stressors. He concluded, “The now
overwhelming evidence that experience can alter neuronal structure and function should
make it clear that it is dangerous to assume that any anatomical or physiological
characteristic found in brains of people with mental disorders was the cause of that
disorder” (p. 128). A study at UCLA focused upon brain functioning with obsessive-
compulsive disorder (OCD). Continuous monitoring of brain activity in the patients as
they received either medication or behavioral therapy showed that both treatments
modified brain activity (and overt functioning) equally well (Friedman, 2002).
PET scan and fMRI studies frequently show that chronically mentally disordered
individuals have enlarged ventricles or unusual protein levels in the brain, or differential
brain metabolism compared to the brains of those who suffer no mental disorder (Wyatt,
2003). But causality cannot be determined based upon such brain differences. Did these
brain abnormalities cause the individuals’ mental disorders? Or did years of suffering
from a disorder cause changes in their brains? The latter question is not as quirky as it
may seem. Valenstein (1998) presented the case of the Dexamethasone Suppression Test
(DST) as an example that had misled the clinical and scientific communities.
Dexamethasone is a synthetic hormone that functions somewhat like the hormone
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cortisol, a hormone that has been shown to be elevated in depressed individuals. It was
found that upon receiving an injection of DST, the cortisol levels of depressed individuals
were suppressed for a significantly shorter period than were the cortisol levels in
individuals who were not depressed. As a result, by the 1980s the DST was thought to
have detected a biological marker for depression. However, subsequent research showed
that the DST had not revealed a brain abnormality that caused depression. Rather, the test
reflected the loss of appetite and lowered food intake of most depressed individuals
(Mullen, Linsell & Parker, 1986).
We know that depressed individuals tend to sleep and eat poorly, and they often get
less physical and mental exercise than do non-depressed individuals. Years of living a
depressed lifestyle may change one’s physiology. The depressed person’s health may
change in overt ways as he becomes lethargic and loses muscle tone. There also may be
unobserved changes in brain physiology and chemistry that result from failure to
maintain a stimulating routine of enjoyable, productive activity. In fact, it would be quite
surprising if there were not at least some identifiable internal changes, including changes
in the brain, that occur in individuals who live specific lifestyles. The chronically anxious
person may ultimately undergo changes in his gastrointestinal tract, as excess stomach
acid causes an ulcer. Brain changes likely take place at the same time. Both the G-I tract
changes and the brain changes may be the results of stress, rather than causes of stress-
related mental disorders.
When one looks beyond difficulties in determining the direction of causality, one
finds philosophical and methodological problems in brain imaging studies. Chief among
them is the difficulty in defining hypothetical underlying mental processes. Added to the
disagreement as to what constitutes the components of human thought is the questionable
assumption of localization of mental processes. The brain is highly complex, its regions
are interconnected at microscopic levels. The fundamental idea that brain imaging
techniques can localize any cognitive or emotional process to a single area of the brain is
questionable (Faux, 2002; Uttal, 2004; Uttal, 2001).
Among the methodological and interpretative problems in PET and fMRI studies is
the subtraction method of data collection. The method involves the collection of baseline
brain images as a subject completes a task not involving a specific cognitive process.
Then that cognitive process is added to the task. Differences in the sets of images are
observed across many subjects. The averages of these differences are said to localize the
regions that account for the cognitive process under study. However, the subtraction
method rests on several questionable assumptions including that a single brain operation
is at work for a given mental process, and that neurological importance applies only to
the rather large brain areas that have been “localized” (Faux, 2002). One may question, as
well, the practical usefulness of average differences in brain functioning.
Moreover, there have been highly inconsistent findings across studies of brain
imaging. For example, a review (Cabeza & Nyberg, 1997) of 73 PET studies showed that
across only five studies that used the same task (in an effort to localize “attention”),
twenty areas of the brain were found to be involved. The fundamental assumption that
cognitive processes can be localized may itself be wrong (Uttal, 2001).
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One researcher summarized the reliance upon brain imaging saying, “What is clear
is that there has been a rather reckless community decision to commit an inordinate
portion of psychology’s limited resources to this one research program” (Uttal, 2004). As
with the studies of identical twins, studies done on autopsy and studies using imaging are
able to provide little evidence that mental disorders have their genesis in our biology.
A CHALLENGE TO BIOLOGICAL PSYCHIATRY
On July 28, 2003 an organization called Mind Freedom issued a challenge to three
high profile proponents of the theory that our biology causes mental disorders (Mind
Freedom, 2003). Mind Freedom is a loose-knit federation comprised mainly of
professionals and former patients. They believe that claims of biological causation have
gone too far and are hurting patients. The group also disputes many of the claims of
effectiveness of psychotropic medications.
The three organizations that were challenged by Mind Freedom were the American
Psychiatric Association (APA), The National Alliance for the Mentally Ill (NAMI), and
the Office of the Surgeon General of the United States (OSG). Mind Freedom challenged
the three to produce any scientifically valid evidence to show that schizophrenia,
depression or other mental disorders (apart from the obvious such as Down’s syndrome,
autism, and those that are clearly brought on by identifiable tumors, infection, etc.) are
biologically based. Mind Freedom also challenged the three groups to prove that there is
any physical diagnostic test which can reliably distinguish those so diagnosed from
“normals.” Next, Mind Freedom asked for any evidence that would demonstrate the
existence of a chemically balanced “normal” personality against which a neurochemical
“imbalance” may be compared. Finally, Mind Freedom asked APA, NAMI and the OSG
to produce scientific evidence that any psychotropic medication can correct a “chemical
imbalance” or decrease the likelihood of violence or suicide.
Mind Freedom’s challenge drew a response from James H. Scully, Jr., MD, Medical
Director of the American Psychiatric Association. In a letter dated August 12, 2003,
Scully affirmed psychiatry’s support of biological causation: “The answers to your
questions are widely available in the scientific literature and have been for years…”
Scully wrote. He advised Mind Freedom to see five sources. The five included a report
by the Surgeon General; the third edition of the Introductory Textbook of Psychiatry
(Andreason & Black, 2001); the fourth edition of the Textbook of Clinical Psychiatry
(Hales & Yodofsky, 2003); or any recent issues of either the American Journal of
Psychiatry (Andreasen, 2003) or the Archives of General Psychiatry (Barchas, 2003).
Mind Freedom replied to Dr. Scully ten days later. The sources he had cited, Mind
Freedom pointed out, provided little support for biological causation of mental disorders.
For example, the Surgeon General’s report contains statements such as, “The precise
causes (etiology) of mental disorders are not known” (p. 49). The Textbook of Clinical
Psychiatry states, “Although reliable criteria have been constructed for many psychiatric
disorders, validation of the diagnostic categories as specific entities has not been
established” (p. 43). The Introductory Textbook of Psychiatry states, “Much of the current
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investigative research in psychiatry is directed toward the goal of identifying the
pathophysiology and etiology of major mental illnesses, but this goal has been achieved
for only a few disorders (Alzheimer’s disease, multi-infarct dementia, Huntington’s
disease, and substance induced syndromes such as amphetamine-related psychosis or
Wernicke-Korsakoff syndrome)” (p. 23). Mind Freedom requested that Dr. Scully point
specifically to any supporting research within the over 200 volumes of the journals he
had cited.
The American Psychiatric Association responded again to Mind Freedom, this time
with a position statement in which it held to the position that mental disorders are
“neurobiological.” The APA’s statement asserts, in part, that there has been
“…remarkable scientific and clinical progress (in the) understanding of disorders that
afflict and are mediated by the brain…” However, no citations or references beyond those
previously cited by Dr. Scully were listed. The APA’s position statement was
unsatisfying for another reason. It also said, in part, “…brain science has not advanced to
the point where scientists or clinicians can point to readily discernible pathologic lesions
or genetic abnormalities that in and of themselves serve as reliable or predictive
biomarkers of a given mental disorder or mental disorders as a group…” (Mind Freedom,
2003).
A viable conclusion is that the American Psychiatric Association is engaged in self-
serving advocacy of biological causation, and that it does so in the absence of conclusive
scientific evidence. The psychiatric guild is evidently urging blind faith in the theory of
biological causation, but is unable to produce the research evidence that would confirm it.
As was written in Hospital and Community Psychiatry more than twenty years ago,
“Medicalization is useful to rout the enemy….”
EFFICACY OF PSYCHOTROPIC MEDICATIONS
If organized psychiatry bases many of its assertions as much on faith as upon
evidence, what of the claims of pharmaceutical companies that medications represent
effective treatments for depression, anxiety, schizophrenia and other disorders?
Increasingly, the effectiveness of psychotropic medications is being called into question
(Friedman, 2004). Although testimonials and anecdotal reports are common, they do not
substitute for double-blind, placebo-controlled studies.
When one looks at participants in such studies, it becomes evident that they often are
not representative of typical patients. For example, it is routine that pregnant women,
lactating women and women of childbearing years who are not using contraceptives are
excluded from studies of new drugs (which is as it should be). Also generally excluded
from the studies of drug efficacy are many other kinds of patients. They include those
who suffer from any mental disorder other than that which the drug is designed to treat;
patients with any serious medical illness; patients with significant lab test results; patients
with EKG abnormalities; patients receiving anticoagulants; patients with positive drug
screens; patients with suicidal ideas; and patients who have ever received cognitive
behavioral therapy or electroconvulsive shock treatment. Once such patients are
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eliminated, the remaining pool of potential drug study subjects is less than representative
of the population that the drug eventually may be used to treat. Brown University’s Mark
Zimmerman noted with evident chagrin that 86% of the depressed patients he saw would
have been excluded from studies of anti-depressants. Yet, he had prescribed the
medications for 93% of them (Wyatt, 2003).
Another question is whether psychotropic medications actually live up to their
advertised claims of effectiveness. One review of ninety-six antidepressant trials between
1976-1996 found that in 52% of the studies there was no difference between drug effect
and placebo effect. The Eli Lilly Company had to run five studies of Prozac to obtain two
(the FDA minimum for approval) that showed positive effects. Paxil and Zoloft required
even more trials to get two that were positive (Kahn, Leventhal, Kahn & Brown, 2002). It
would be irresponsible to argue that no one is helped by psychotropic medications.
However, there is reason to conclude that the medications are less helpful than was
previously thought.
Even when drug study results are positive, a routine methodology leaves
interpretation in limbo. The procedure in question causes the research to be carried out in
a way that boosts the likelihood that the drug will be found effective. Prior to the start of
a drug study researchers actively attempt to cull from the subject pool all patients who
might respond favorably to the placebo. Before placing patients into either the drug group
or the placebo group, all are given the placebo and observed for up to three weeks. This is
termed the placebo “run-in” or “wash-out” period. Those who improved while taking
placebo are removed from the subject pool. They have no further participation in the
study. Then the remaining subjects are divided into drug and placebo groups and the
study is conducted. The practical result is that the deck is stacked to show that the drug is
more effective than placebo. It is difficult to defend as suitable methodology, although it
is done routinely by drug researchers.
Even so, the results of drug studies are frequently negative, or are only marginally
positive. For example, a review was undertaken of thirty-eight studies of anti-depressants
such as Prozac, Zoloft, Paxil, Serzone, Celexa and Effexor that had been done during
1987-1999. On the 50-point Hamilton Depression Scale the studies showed an average
10-point improvement in mood for patients who took the drugs, and an 8-point
improvement for those who took a placebo (Kirsch, Moore, Scoboria & Nicholls, 2002).
It is doubtful that the two-point average advantage for the drugs is meaningful in the real
world in which patients function every day, or that the drugs would have had even that
slight advantage over placebo had it not been for the wash-out methodology.
The pharmaceutical industry continues to aggressively market its psychotropic
drugs. Since the mid-1990s it has doubled the number of its employees in marketing and
advertising, while the number employed in research and development has dropped
slightly. The former now outnumber the latter by about two to one (Sagar & Socolar,
2001). The industry has recently stepped up its efforts to target children. According to the
pharmacy benefit management company Express Scripts, pre-schoolers are the fastest
growing market segment for antidepressants. During 1998-2002 prescriptions of
antidepressants for boys under age five increased 64%. For pre-school girls the increase
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was 100% (Johnson, 2004). However, it has been known for some time that
antidepressants often are not effective or are only marginally effective for children
(Sommers-Flanagan & Sommers-Flanagan, 1996).
The absence of compelling results of drug trials may explain why drug companies
now sometimes hire ghostwriters to author the studies they fund. Although the studies
may be conducted by respected faculty members at highly visible universities, it is fairly
common for ghostwriters far from the lab to write the published versions of the results.
Ghostwriting has been especially noted to occur in psychiatry journals, and Pfizer
pharmaceutical company employs a New York medical writing agency, according to a
recent lawsuit disclosure (Barnett, 2003).
For the drug industry the economic stakes are so high that principles of good
practice may at times be compromised. Recently drug giant Pfizer agreed to pay $430
million to settle a fraud case involving its anti-epilepsy drug Neurontin. Pfizer had
purchased Warner-Lambert, which had been illegally marketing the drug off-label (non-
approved by the FDA) for psychiatric problems such as bipolar disorder and attention
deficit hyperactivity disorder. Using the off-label marketing strategy, sales of the drug
had escalated 2,700%, from $97.5 million in 1995 to $2.7 billion in 2003. Although
evidently the illegal marketing practice stopped in 2000, and even though the penalty
paid by Pfizer seems severe, the amount paid represents only about 15% of the gross
sales of Neurontin in 2003 alone. While the marketing of Neurontin off-label has been
stopped, it is still legal for doctors to prescribe it off-label, and the effects of the earlier
illegal marketing evidently continue, as prescriptions written continue to spiral upward
(Farrell, 2004).
TURF, MONEY AND POWER
It is not the purpose of this article to advocate for an exclusive environmentalism. As
discussed in the opening section, there is no dispute that several mental and behavioral
disorders are biologically caused, and that others may be the result of the interaction of
biological and environmental variables. Rather, our view is consistent with that of
Skinner’s as articulated decades ago. He wrote that “…genetic sources sometimes
become a kind of dumping ground: any aspect of behavior which at the moment escapes
analysis in terms of contingencies of reinforcement is likely to be assigned to genetic
endowment…” (Skinner, 1974). In fact, one of the foundational principles of the
behavioral point of view is that we are genetically endowed with the capacity to change
our behavior, based upon its consequences.
Nor is it our purpose here to claim that psychotropic medications are never of help.
Certainly anti-anxiety medications usually bring about temporary relaxation. Anti-
psychotic medications, if they do not cure psychosis, are at times able to render such
disorders more tolerable to patients, and communities more tolerant toward patients.
Although the evidence in support of anti-depressants and other psychotropic medications
is weaker, surely they are beneficial at times.
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Our purpose here is to make clear that biological explanations have gone too
far—well beyond the data. The pharmaceutical industry has made questionable claims of
biological causation in order to build its profits. Other groups, though perhaps not as
powerful as the drug industry, have done the same. Members of the American Psychiatric
Association become the treaters of choice. Patient advocacy groups such as the National
Alliance for the Mentally Ill (NAMI) and the National Alliance for Research on
Schizophrenia and Depression (NARSAD) also push the biological causation perspective.
Each receives substantial financial support from the drug industry and, in turn, each
pushes the biological causation model with the Congress and the public. Literature from
such groups often emphasizes medication as the preferred treatment (Wyatt, 2003).
The one-two efforts of organized psychiatry and the pharmaceutical industry have
had enormous impact upon mental health care in America. Evident as well is that the
claims by these two groups are symbiotic. Each supports the other in their quests for turf,
money and power. Psychiatry and the pharmaceutical companies play upon the patient’s
desire to be told that his psychological disorder or adjustment difficulty is not his fault, is
not due to a lack of will or character, but rather is due to his biological make-up. Some
therapists now say that an initial major task of therapy is to undo the new patient’s
assumption that his or her difficulty is rooted in biology (Wyatt, 2003).
Patients are being shortchanged. One study showed that when genetic causation is
assumed, patients indeed feel less responsible. However, they are also less likely to think
they can improve with appropriate help. In addition, they are more likely to assume that
others in the family will develop the same problem (Phelan, 2002). They may then
become more likely to depend upon medications, less likely to seek therapy that might
provide them with improved coping skills or other enduring changes.
It is time for a paradigm shift, away from extreme biological causation and toward
an environmental causation model, one that recognizes that at least some disorders are
biologically caused. We are not optimistic that our culture will change anytime soon. Our
pessimism comes after careful examination of the rise of biological causation theory, a
phenomenon that has come about as a direct result of the powerful influences of
organized psychiatry and the pharmaceutical industry. Their impact is far-reaching,
unyielding and seductive to the unwashed. Mental health treatment careens under the
influence. Ironically, there could scarcely be better evidence of the environment’s impact
upon us.
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